FLAME 2020
Medical Marijuana and the Opioid Crisis
Report Highlights
Just in 2017, medical cannabis totaled $7.3 billion, up from $4.8 billion in 2016. This segment will likely achieve a 22.2% CAGR to reach nearly $19.8 billion at the producer level in 2022 and will account to more than 80% of the global market.
Politics aside, one must remember that marijuana is still a drug and needs to be treated as such with its potential side effects.
Even if cannabinoids-based drugs will not fully substitute opioid use, combination of medical marijuana use with reduced dose of opioid will help to curb the crisis.
Report Includes
- Short introduction to what is medical marijuana: definition and main active compounds (cannabinoids)
- Current uses of medical marihuana: epilepsy, inflammation, especially as pain medication for cancer patients
- Approved products on the market containing medical marihuana/cannabinoids
- Current manufacturers of medical marijuana
- Information on medical marijuana in drug development market (examples of some companies)
- How medical marijuana is different from opioids and how/if it helps with the crisis
- Effect of legislation on medical marijuana sector: potential trends in medical marijuana market, new opportunities and products
Analyst Credentials
Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology and industrial assay development and drug manufacturing. She has contributed to a number of scientific publications and holds several patents. She has expertise as an assay development scientist and is familiar with different research field trends and likely future developments.
